Daniel Perry is Director of Federal Affairs at the Council of Canadian Innovators (CCI), where he leads national advocacy on behalf of Canada's high-growth scale-up companies. Named to The Hill Times' Top 100 Lobbyists for 2026, he has testified this year before three House of Commons standing committees — Industry and Technology, Finance, and Citizenship and Immigration — each time making the same case: capital, customers, talent, and sectoral strategy aren't separate policy files,

This audio brief covers key developments from Boehringer Ingelheim, Roche, Fresenius and Sanofi, including clinical trial readouts, regulatory and product advancements, and corporate acquisitions.It was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

Building the Autonomous Pharma Factory What happens when artificial intelligence, robotics, IoT, digital twins, and advanced analytics come together to transform pharmaceutical manufacturing? In this episode of Center of Excellence - Pharma 4.0, we explore the evolution from traditional, fragile manufacturing systems to the Autonomous Pharma Factory—a self-optimising, resilient and digitally connected manufacturing environment. In this episode, we explore: Why pharmaceutical manufacturing needs

Today, in partnership with British Heart Foundation (BHF), we take on the world's biggest killer: heart disease. This episode features BHF's Ruth Goss on why this disease kills so many people; Will Watson at the Royal Papworth Hospital in Cambridge on what arterial disease looks like under a microscope; Cathy Shanahan at King's College London on attempts to stop blood vessels from becoming hard and stiff; and BHF's Sonya Babu-Narayan on risk management and heart disease treatment. Like this podcast

*آیا شعر و ادبیات فارسی به رشد خردورزی کمک کرده‌اند یا به تقویت تقدیرگرایی؟ آیا شعر فارسی د‌وره هایی از شکوفایی و انحطاط رو از سر گذرانده؟* در بخش اول این سری گفتگوها از پادکست هشیوار، با حضوری جمعی از پژوهشگران و صاحب‌نظران برجسته، به نقد و ارزیابی نقش شعر و ادبیات کلاسیک فارسی در شکل‌گیری خرد نقاد، آزادی اندیشه، سنجش باورها و نقد قدرت می‌پردازیم. ادبیات فارسی به‌عنوان مهم‌ترین رکن هویت فرهنگی ایرانیان، همواره نقشی ژرف بر شیوه اندیشیدن و جهان‌بینی ما داشته است. اما آیا این میراث ارزشمند بیشت...

What if the distance from Africa isn't about history, but about pain?  In this powerful episode, we explore the deep connection between Black American culture and African heritage through music, food, faith, and language, while confronting the wounds, shame, and narratives that have shaped identity across generations. This is not a debate about labels. It's an invitation to healing, truth, and reclaiming the parts of ourselves that were never lost, only buried.  Join us for a courageous conversation

Biotech loves talk of disruptive technology, but few have repeatedly shifted the industry's direction. This episode of the Smart Biotech Scientist Podcast focuses on an idea once dismissed as a fool's game: process intensification through perfusion—now the backbone of leading biomanufacturing platforms. Meet John Bonham-Carter, a serial entrepreneur whose fingerprints are on some of biotech's most transformative tools. From putting the once-ignored ATF system and perfusion on the global stage...

Send us Fan Mail Europe looks like one market on a map, but try bringing a drug across borders and you quickly learn it behaves like many systems at once. We sit down with Daphne Smyth, a regulatory leader based in Ireland with 35+ years in pharmaceutical regulatory affairs, to unpack a mistake we keep seeing: companies build commercial teams first, then discover they have not built the regulatory pathway needed to launch at all. The result is not just delay, it is avoidable rework in clinica...

Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals. The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing and li...

🔥❤️ في هذا الفيديو، يظهر موزو بإطلالة جديدة ويفاجئ المتابعين بخطوة غير متوقعة. 😳✨ لكن ماذا يحدث لموزو في المستشفى؟ 🏥👀😱❤️ موقف أثار فضول المعجبين وجعل الكثيرين يتساءلون عمّا حدث بالفعل.🥰 تابعوا الفيديو حتى النهاية لاكتشاف جميع التفاصيل ومتابعة آخر المستجدات!👍 لا تنسوا الإعجاب، 💬 التعليق، 📲 المشاركة، والاشتراك في القناة 🔔❤️.

In this episode of Modern Parenthood, Nicole shares the emotional reality of adoption, the uncertainty adoptive parents experience before parental rights are surrendered, navigating another miscarriage while caring for her newborn son, and why she ultimately decided to pursue IVF.00:00 - The Emotional Reality of Adoption02:18 - Choosing Adoption After Pregnancy Loss03:29 - Pregnant Again While Waiting to Adopt05:20 - What Happens Before an Adoption Is Final?06:39 - Why Adoption Can Bring Both Joy

Send us Fan Mail This episode of "The UMB Pulse" explores why health care can feel fragmented when patients must repeat medical histories and providers don’t seem to communicate. Kenneth H. Wong, PhD, University of Maryland, Baltimore’s vice provost for graduate education and dean of the School of Graduate Studies, explains that the issue is driven less by individual unwillingness than by systems and structures that discourage coordination and lack a clear “general contractor” role. He...

Why are we here? Does life, or the universe, mean anything? And if it does, what? Today on ID The Future, host Andrew McDiarmid explores those questions and more with physicist and author Dr. Eric Hedin. Using the recent documentary film The Story of Everything as a springboard for discussion, Hedin shows that cumulative scientific evidence is pointing to a purposeful universe, not a cosmic accident. This is Part 1 of a two-part conversation. Look for Part 2 next!Source

Oncolytic viruses may offer a new way to tackle solid tumors by targeting cancer cells and activating the immune system. Dr. Eric Poma explains how Calidi Biotherapeutics is engineering a vaccinia-based virus to evade immune clearance, reach tumors, and deliver an immune-stimulating payload. He and Kevin Folta discuss the approach’s potential for cancers such as lung cancer, melanoma, renal cancer, and head and neck cancers.

Oncology AI is moving closer to clinical decisions: estimating treatment benefit, mapping risk, and handling incomplete evidence. This coverage shows why stronger prediction and better care remain separate…

Tim Opler, Managing Director at Stifel, discusses why bioinnovation should be understood as a public good and how drug costs can undermine public trust in the life sciences. He explores the widening funding gap between early- and late-stage biotech, the effects of M&A and interest rates, how AI could reshape medicine around consumers, and what it takes to build a lasting life sciences ecosystem in Georgia.About Georgia Life SciencesAs the leading advocate for the state’s dynamic and diverse life

Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.

Christophe has run MedinCell since 2009, when it was eight people in a converted garage. Today it's one of only three French biotechs to ever cross $1B on Euronext.With one Teva-partnered product already a commercial success, the partners are potentially weeks away from getting FDA approval for a second.We also talked about France’s biotech giants, the landscape of long-acting injectables, and why Christophe was once in charge of a remote fishing lodge in Canada.---Discover the best biotech

n this episode of The Cancer Project, we sit down with ovarian cancer survivor and author Anna Focht. In 2015, what began as a routine annual appointment quickly changed Anna’s life when her doctor discovered a lump during a pelvic exam. Diagnosed with stage three B ovarian cancer, Anna underwent surgery followed by 18 weeks of chemotherapy while navigating treatment and trying to remain present for her family.Anna opens up about the physical and emotional realities of her cancer journey, from the

Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.